Erin Fogel, MD
Ophthalmology · Concord, NHNPI 1417941808
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,862 of the $3,594 with a category attached, or 79.6%. It is spread thinly across 27 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,782 and has fallen 85.6% since, to $257 in 2025.
Across 79 payments — averaging $45.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$774
- Bausch & Lomb Americas Inc.$283
- Bausch & Lomb, A Division Of Bausch Health US, LLC$279
- Rxsight Inc$276
- Glaukos Corporation$256
- Alcon$240
- plus $1K from 21 others
What the payments were for
- Consulting fees$73220%
- Food & beverage$2,86280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 4 | $774 |
| Bausch & Lomb Americas Inc. | 7 | $283 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $279 |
| Rxsight Inc | 2 | $276 |
| Glaukos Corporation | 3 | $256 |
| Alcon | 5 | $240 |
| AbbVie(2 entities) | 6 | $200 |
| Dompe US, Inc. | 4 | $193 |
| Avedro Inc. | 1 | $126 |
| Genentech USA, Inc. | 1 | $117 |
| Aerie Pharmaceuticals, Inc. | 1 | $86 |
| Regeneron Healthcare Solutions, Inc. | 5 | $85 |
| Amgen | 1 | $82 |
| Oyster Point Pharma, Inc. | 4 | $75 |
| Sun Pharmaceutical Industries Inc. | 4 | $66 |
| Carl Zeiss Meditec, Inc. | 1 | $65 |
| Optovue, Inc. | 1 | $63 |
| Biotissue Holdings Inc. | 3 | $57 |
| Harrow Eye, LLC | 2 | $45 |
| Tarsus Pharmaceuticals, Inc. | 1 | $40 |
| Rayner Intraocular Lenses Limited | 2 | $38 |
| Omeros Corporation | 2 | $34 |
| Eyevance Pharmaceuticals LLC | 2 | $30 |
| Sight Sciences, Inc. | 1 | $23 |
| Novartis | 1 | $22 |
| Shire North American Group Inc | 1 | $19 |
| Thea Pharma Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis Symfony IOL$732
- RXSIGHT CONTACT LENS$276
- RXSIGHT INJECTOR CARTRIDGE$276
- RXSIGHT INJECTOR HANDPIECE$276
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$276
- iStent inject Trabecular Micro-Bypass Stent System$168
- LIGHT ADJUSTABLE LENS (LAL)$163
- TORIC$156
- Oxervate$120
- Lucentis$117
- ARGOS$115
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$113
How this compares
$3,594 in reported general payments places this provider in the 75th percentile of 80 ophthalmology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 76 | $69,168 |
| RestasisCyclosporine | 54 | $48,726 |
| Fluorometholone | 628 | $38,055 |
| ProlensaBromfenac Sodium | 85 | $34,514 |
| Bromfenac Sodium | 123 | $25,840 |
| Prednisolone Acetate | 716 | $24,778 |
| Cyclosporine | 50 | $19,449 |
| LotemaxLoteprednol Etabonate | 35 | $13,464 |
| ValacyclovirValacyclovir Hcl | 173 | $9,074 |
| LumiganBimatoprost | 19 | $6,980 |
| CequaCyclosporine | 11 | $6,108 |
| Ofloxacin | 440 | $5,922 |
| ZirganGanciclovir | 12 | $5,631 |
| Loteprednol Etabonate | 29 | $4,930 |
| VyzultaLatanoprostene Bunod | 15 | $4,026 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Zirgan, Vyzulta | $283 | $78,825103 claims |
| AbbVieRestasis, Lumigan, Alphagan P | $200 | $59,21088 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax, Loteprednol Etabonate | $279 | $52,908149 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $66 | $6,10811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 80 ophthalmology providers in New Hampshire.
Other ophthalmology in Concord
- Christie MorseConcord$6K
- Jerome Ramos-EstebanConcord$3K
- Tighe RichardsonConcord$2K
- Purvi ShahConcord$638
- Maxwell SneadConcord$397
- Catherine MarandoConcord$288
- Brett SmithConcord$237
- Bradford HallConcord$202
- Dane SlentzDerry$127K
- Jason SzelogPortsmouth$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.